Submit Deal

TCG CROSSOVER

Summary

TCG Crossover is a science-driven investment firm dedicated to advancing disruptive medicines.

Deals Overview

Total Deals6

Valued Deals6

Total Value£ 644 M

Avg. Deal Size£ 107 M

Market Context

Sort

entrada therapeutics inc

HQ - United States

Biotechnology

31 Mar 2021

Investment Date

£ 84 M

Deal Value

affinia therapeutics

HQ - United States

Biotechnology

3 May 2021

Investment Date

£ 80 M

Deal Value

artios pharma limited

HQ - United Kingdom

Biotechnology

27 Jul 2021

Investment Date

£ 110 M

Deal Value

arbor biothechnologies

HQ - United States

Pharmaceuticals

9 Nov 2021

Investment Date

£ 159 M

Deal Value

beacon therapeutics

HQ - United States

Health Care Services

3 Jul 2024

Investment Date

£ 134 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy